Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 8 (August)

1. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
   Anticancer Drugs, 18(8): 969-72. [Abstract] [Full-text]
2. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.
   Pharm Res, 24(9): 1720-8. [Abstract] [Full-text]
3. Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
   J Clin Invest, 117(8): 2114-22. [Abstract] [Full-text]
4. Applying the discovery of the Philadelphia chromosome.
   J Clin Invest, 117(8): 2067-74. [Abstract] [Full-text]
5. Treatment for chronic myelogenous leukemia: the long road to imatinib.
   J Clin Invest, 117(8): 2036-43. [Abstract] [Full-text]
6. Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations.
   Clin Cancer Res, 13(15): s4632-6. [Abstract] [Full-text]
7. Possible roles of neuropeptide Y Y3-receptor subtype in rat aortic endothelial cell proliferation under hypoxia, and its specific signal transduction.
   Am J Physiol Heart Circ Physiol, 293(2): H959-67. [Abstract] [Full-text]
8. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
   J Nucl Med, 48(8): 1245-50. [Abstract] [Full-text]
9. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.
   Blood, 110(4): 1283-90. [Abstract] [Full-text]
10. Congestive heart failure is a rare event in patients receiving imatinib therapy.
    Blood, 110(4): 1233-7. [Abstract] [Full-text]
11. Are MAP Kinases Drug Targets? Yes, but Difficult Ones.
    ChemMedChem, 2(8): 1116-1140. [Abstract] [Full-text]
12. A Radioprotective Effect of Imatinib (Gleevec((R))) in Human Squamous Carcinoma Cells.
    Strahlenther Onkol, 183(8): 432-439. [Abstract] [Full-text]
13. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Cancer, 110(4): 801-8. [Abstract] [Full-text]
14. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    J Transl Med, 5: 32. [Abstract] [Full-text]
15. Roots of imatinib resistance: A question of self-renewal?
    Drug Resist Updat. [Abstract] [Full-text]
16. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.
    Thorax, 62(8): 690-5. [Abstract] [Full-text]
17. Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway.
    Dig Dis Sci, 52(9): 2292-300. [Abstract] [Full-text]
18. What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?
    Leuk Res, 31(10): 1445-7. [Abstract] [Full-text]
19. Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
    Leuk Res, 31(10): 1441-4. [Abstract] [Full-text]
20. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome.
    Am J Hematol, 82(9): 849-51. [Abstract] [Full-text]
21. Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice.
    Mod Rheumatol, 17(4): 306-10. [Abstract] [Full-text]
22. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
    Bone Marrow Transplant, 40(5): 423-30. [Abstract] [Full-text]
23. Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases.
    Skeletal Radiol, 36(9): 895-8. [Abstract] [Full-text]
24. Exploring sequence-structure relationships in the tyrosine kinome space: functional classification of the binding specificity mechanisms for cancer therapeutics.
    Bioinformatics, 23(15): 1919-26. [Abstract] [Full-text]
25. Epigenetic control of MAGE gene expression by the KIT tyrosine kinase.
    J Invest Dermatol, 127(9): 2123-8. [Abstract] [Full-text]
26. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
    Proc Natl Acad Sci U S A, 104(33): 13283-8. [Abstract] [Full-text]
27. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
    Clin Cancer Res, 13(16): 4874-81. [Abstract] [Full-text]
28. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
    Cell Death Differ, 14(9): 1667-77. [Abstract] [Full-text]
29. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat.
    Int J Androl, 30(4): 366-76. [Abstract] [Full-text]
30. Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
    Anticancer Drugs, 18(9): 1029-37. [Abstract] [Full-text]
31. Recent advances in the treatment of salivary gland cancers: Emphasis on molecular targeted therapy.
    Oral Oncol, 43(8): 729-34. [Abstract] [Full-text]
32. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
    J Pharmacol Exp Ther, 322(3): 1084-92. [Abstract] [Full-text]
33. Successful resection of a giant recurrent gastrointestinal stromal tumour with imatinib mesylate as neoadjuvant therapy.
    Scand J Gastroenterol, 42(9): 1138-40. [Abstract] [Full-text]
34. Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
    Leukemia, 21(9): 1971-6. [Abstract] [Full-text]
35. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
    Blood, 110(5): 1612-20. [Abstract] [Full-text]
36. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
    Ann Hematol, 86(10): 749-52. [Abstract] [Full-text]
37. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Mol Pharmacol, 72(3): 788-95. [Abstract] [Full-text]
38. Crystal Structure of the T315I Mutant of AbI Kinase.
    Chem Biol Drug Des, 70(3): 171-81. [Abstract] [Full-text]
39. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
    Cytokine Growth Factor Rev, 18(5): 459-71. [Abstract] [Full-text]
40. Molecular basis for sunitinib efficacy and future clinical development.
    Nat Rev Drug Discov, 6(9): 734-45. [Abstract] [Full-text]
41. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
    J Clin Oncol, 25(25): 3908-14. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.